Cyclacel Pharmaceuticals, Inc.
200 Connell Drive
Suite 1500
Berkeley Heights,
NJ 07922
United States - Map
Phone: 908-517-7330
Fax: 866-271-3466
Web Site: http://www.cyclacel.com
| Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Its orally-available drugs in clinical development include Sapacitabine (CYC682), an oral nucleoside analogue, which is in phase II studies for the treatment of hematological malignancies, such as acute myeloid leukemia in the elderly, myelodysplastic syndromes, cutaneous T-cell lymphoma, and lung cancer; Seliciclib (CYC202), a CDK (cyclin dependent kinase) inhibitor, which is in phase II studies for the treatment of lung cancer and nasopharyngeal cancer; and CYC116, an Aurora kinase and VEGFR2 inhibitor that is in phase I studies for patients with solid tumors. The company, through its subsidiary, ALIGN Pharmaceuticals, LLC, markets directly Xclair Cream for radiation dermatitis, as well as Numoisyn Liquid and Numoisyn Lozenges for xerostomia in the United States. It focuses on building a diversified biopharmaceutical business focused in hematology, oncology, and other therapeutic areas based on a portfolio of commercial products and a development pipeline of novel drug candidates. The company was founded in 1992 and is headquartered in Berkeley Heights, New Jersey. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Spiro Rombotis , 50
Chief Exec. Officer, Pres and Exec. Director |
$
620.00K | N/A | Mr. Paul Mcbarron , 48
Chief Operating Officer, Chief Financial Officer, Exec. VP of Fin., Sec. and Exec. Director |
$
355.00K | N/A | Dr. Judy H. Chiao M.d., 48
Chief Medical Officer and VP of Clinical Devel. and Regulatory Affairs |
$
385.00K | N/A | Prof. David Glover FRSE, 61
Chief Scientist of Polgen Division |
N/A
| N/A | Dr. Peter Fischer Ph.D., 52
Head of Drug Discovery |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.14% Nasdaq 
Profile
